Video – how the LRC-TriCEPS™ technology works

Dualsystems Biotech AG Press Release

How the LRC-TriCEPS™ technology works (Video)

Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS™) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging from peptides, proteins, antibodies to viruses. Dualsystems offers the LRC-TriCEPS™ technology in our service line CaptiRec. We offer a variety of formats which will fit your needs: From CaptiRec Kits for your own in-house experiments to an all-inclusive CaptiRec Service.

Dualsystems Biotech AG is looking forward to support your project with the newest invention in receptor/target discovery.

Please watch the video where we explain how the LRC-TriCEPS™ technology works: LRC-TriCEPS™-Video

Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology

Dualsystems Biotech AG Press Release

Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology

Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays

Read more

Video interview about CaptiRec Services (LRC)

Video interview of CaptiRec Services, ligand-receptor capture technology (LRC) with Dr. Paul Helbling, the new management of Dualsystems Biotech AG.

 

Dualsystems closes Series C Financing Round

Dualsystems Biotech  has closed a Series C financing round with support from existing and new investors to implement and drive forward its new business strategy in mass spectrometry based protein interaction discovery.

Read more

Dualsystems Biotech sells its yeast two-hybrid (Y2H) activities to Hybrigenics

Dualsystems Biotech is driving its business activities towards new technologies and builds up new strengths in the field of protein interaction discovery.

Read more

Licensing Agreement with ETH Zurich on LRC technoloy

Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS™, which enables the unbiased identification of cell surface receptors for many…